| Title |
COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, March 2008
|
| DOI | 10.2147/ndt.s2404 |
| Pubmed ID | |
| Authors |
Angelo Antonini, Giovanni Abbruzzese, Paolo Barone, Ubaldo Bonuccelli, Leonardo Lopiano, Marco Onofrj, Mario Zappia, Aldo Quattrone |
| Abstract |
Levodopa is the most effective treatment in Parkinson's disease and the association with COMT inhibitors widens its plasma bioavailability and effectiveness. Tolcapone is a potent COMT inhibitor whose utilization in PD is limited due to safety concerns on liver toxicity. However, recent data indicate that if liver function is actively monitored, tolerability is no worse than other currently available therapies. By contrast, administration of tolcapone is associated with significant clinical improvement and benefit involves also non-motor features. In this review we discuss the rationale for the use of tolcapone in association with levodopa and other treatments in PD, and we provide an indirect comparison of current strategies to reduce "off" time. We propose that future guidelines include a trial with tolcapone in all PD patients who continue to complain about motor fluctuations despite treatment with entacapone and/or MAO-B inhibitors. Moreover, we suggest that tolcapone should be considered before surgical or infusional strategies are applied. |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 70 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 21% |
| Student > Ph. D. Student | 13 | 18% |
| Student > Bachelor | 12 | 16% |
| Student > Master | 7 | 10% |
| Student > Doctoral Student | 5 | 7% |
| Other | 10 | 14% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 15% |
| Agricultural and Biological Sciences | 10 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 12% |
| Psychology | 8 | 11% |
| Neuroscience | 5 | 7% |
| Other | 17 | 23% |
| Unknown | 13 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2024.
All research outputs
#8,535,472
of 25,374,917 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,152
of 3,132 outputs
Outputs of similar age
#33,884
of 95,559 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#19
of 29 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,559 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.